Compare Precigen, Inc. with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
USD 1,242 Million (Small Cap)
NA (Loss Making)
NA
0.00%
-0.65
-233.25%
29.66
Revenue and Profits:
Net Sales:
5 Million
(Quarterly Results - Dec 2025)
Net Profit:
-24 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-1.86%
0%
-1.86%
6 Months
7.95%
0%
7.95%
1 Year
211.85%
0%
211.85%
2 Years
216.54%
0%
216.54%
3 Years
236.8%
0%
236.8%
4 Years
236.8%
0%
236.8%
5 Years
-35.63%
0%
-35.63%
Precigen, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-42.55%
EBIT Growth (5y)
1.24%
EBIT to Interest (avg)
-40.83
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-5.13
Sales to Capital Employed (avg)
-0.01
Tax Ratio
1.14%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
39.58%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
29.66
EV to EBIT
-11.28
EV to EBITDA
-11.58
EV to Capital Employed
82.38
EV to Sales
192.55
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-730.17%
ROE (Latest)
-233.25%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bearish
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 34 Schemes (10.92%)
Foreign Institutions
Held by 61 Foreign Institutions (2.47%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
4.60
2.90
58.62%
Operating Profit (PBDIT) excl Other Income
-20.50
-33.70
39.17%
Interest
3.00
0.90
233.33%
Exceptional Items
0.00
-111.50
100.00%
Consolidate Net Profit
-23.50
-146.30
83.94%
Operating Profit Margin (Excl OI)
-4,746.10%
-11,800.50%
705.44%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is 58.62% vs 222.22% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is 83.94% vs -450.00% in Sep 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
9.70
3.90
148.72%
Operating Profit (PBDIT) excl Other Income
-103.40
-90.20
-14.63%
Interest
3.90
0.00
Exceptional Items
-143.40
-40.30
-255.83%
Consolidate Net Profit
-250.60
-126.20
-98.57%
Operating Profit Margin (Excl OI)
-11,007.80%
-24,128.70%
1,312.09%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 148.72% vs -37.10% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -98.57% vs -31.60% in Dec 2024
About Precigen, Inc. 
Precigen, Inc.
Pharmaceuticals & Biotechnology
Precigen, Inc., formerly Intrexon Corporation, forms collaborations to create biologically-based products and processes using synthetic biology. The Company's domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company's synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale. The Company's technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing (LEAP), and ActoBiotics platform.
Company Coordinates 
Company Details
20374 SENECA MEADOWS PARKWAY , GERMANTOWN MD : 20876
Registrar Details






